Fed. Circ. Backs Oxford Nanopore's DNA Tech IP Trial Victory

By Britain Eakin (May 11, 2021, 7:10 PM EDT) -- The Federal Circuit on Tuesday upheld a jury verdict that DNA analysis patents Pacific Biosciences asserted against Oxford Nanopore Technologies Inc. are invalid for lack of enablement, rejecting PacBio's argument that Oxford used fearmongering over COVID-19 to pull off a win.

The precedential opinion said "ample evidence" supported the jury verdict, deflating PacBio's argument that it deserves a new trial because Oxford told jurors during opening remarks — as fears about COVID-19 were ramping up and despite a court order prohibiting such statements — that its products were essential to fighting the pandemic and that PacBio was trying to keep them...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!